Sponsors (20)
The bill centralizes and funds a national biotech strategy to accelerate innovation, build workforce and data infrastructure, and strengthen biosafety—at the cost of higher federal spending, greater centralization of authority, potential advantages for larger firms, and elevated privacy, transparency, and regulatory-scrutiny risks.
Small businesses, biotech firms, and researchers will get clearer, centrally coordinated R&D and regulatory pathways (a single portal and interagency strategy), reducing uncertainty and speeding commercialization.
Scientists, federal staff, and students will benefit from clarified statutory definitions and a designated Director/Office, improving accountability, program eligibility clarity, and faster mobilization of technical advice.
Researchers and hospitals will gain improved biological data infrastructure (standardized definitions, centralized databases, and sustained data support) that makes sharing, analysis, and public-health research faster and more interoperable.
Patients, people with chronic conditions, and health systems face increased privacy and security risk because biological data and information are centralized and more widely shared.
Taxpayers will likely face higher federal spending and ongoing administrative costs to create and staff new offices, programs, and initiatives under the coordinated biotechnology effort.
Consumers, patients, and health-care providers risk reduced regulatory scrutiny because measures to streamline approvals and ease commercialization could accelerate market entry with fewer checks.
Based on analysis of 6 sections of legislative text.
Establishes a White House National Biotechnology Coordination Office and interagency Initiative to coordinate federal biotech R&D, data infrastructure, security, workforce, and commercialization efforts.
Introduced April 9, 2025 by Stephanie I. Bice · Last progress April 9, 2025
Creates a White House National Biotechnology Coordination Office and a cross‑agency National Biotechnology Initiative to coordinate and advance federal biotechnology activities for national security, economic competitiveness, and commercialization. The bill requires participating agencies to name senior leads, share biotechnology data, perform threat and supply‑chain analyses related to foreign adversary activity, improve cybersecurity for biological data and infrastructure, support sustained R&D and biological data resources, and promote workforce development and regulatory coordination. The Office will be led by a Director who advises the President, convenes an interagency committee and expert groups (exempting those groups from the Federal Advisory Committee Act), and helps track and align agency biotechnology spending and activities; agencies must implement Initiative activities consistent with their missions and meet deadlines for creating the Office and committee within 180 days of enactment.